Status:
COMPLETED
Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom.
Lead Sponsor:
AstraZeneca
Conditions:
Heart Failure
Eligibility:
All Genders
Brief Summary
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements i...
Eligibility Criteria
Inclusion
- Age ≥18 years as of study index date; the study index date is date of initiation of treatment with dapagliflozin
- Patient received/receiving treatment with dapagliflozin for HFrEF (EF ≤40%) in accordance with the local dapagliflozin product label
- Signed and dated informed consent prior to enrolment in the study
Exclusion
- Patient is enrolled less than 14 days or more than 60 days following initiation of dapagliflozin
- Prior treatment with dapagliflozin or other SGLT2i treatment
- Initiation of dapagliflozin outside of local HF label
- Diagnosis of Type 1 diabetes prior to enrolment
Key Trial Info
Start Date :
November 29 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 2 2024
Estimated Enrollment :
237 Patients enrolled
Trial Details
Trial ID
NCT05188144
Start Date
November 29 2021
End Date
March 2 2024
Last Update
February 25 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Reading, Berkshire, United Kingdom, RG1 5AN
2
Research Site
Truro, Cornwall, United Kingdom, TR1 3LJ
3
Research Site
Portadown, County Armagh, United Kingdom, BT63 5QQ
4
Research Site
Barnstaple, Devon, United Kingdom, EX31 4JB